This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Stangel, M. Search for Related Content Social Bookmarking                   What's this?

Review: New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins

Department of Neurology Hannover Medical School Carl-Neuberg-Str. 1 30625 Hannover Germany, stangel.martin{at}mhhannover.de

Since the incidental discovery in 1981 that intravenous immunoglobulins (IVIg) are immunomodulatory, they have been investigated in a large number of putative autoimmune diseases. This has led to licensing for idiopathic thrombocytopenic purpura, Kawasaki disease, and in neurological disorders for Guillain-Barré syndrome (GBS). Although not licensed, randomized controlled trials have also shown IVIg efficacy in other neuroimmunological diseases such as multifocal motor neuropathy (MMN), chronic inflammatory demyelinating neuropathy (CIDP), myasthenia gravis, dermatomyositis, and stiff-person syndrome. However, other indications are currently being explored including Alzheimer's disease, postpolio syndrome, and narcolepsy. There are even reports from experimental studies in stroke. The results of recently published clinical trials in both the classical neuroimmunological disorders as well as for new indications are reported and their role in clinical practice is discussed.

Key Words: Intravenous immunoglobulins • IVIg • neuroimmunology • immunomodulation

Therapeutic Advances in Neurological Disorders, Vol. 1, No. 2, 115-124 (2008)
DOI: 10.1177/1756285608095747


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?